Telesis Bio closes $28M private placement of preferred stock and warrants; appoints Paul Meister to board

Telesis Bio Inc.

Initial gross proceeds of $28.0M from private placement of redeemable convertible preferred stock and warrants.
Warrants could provide up to $46.2M in additional proceeds if cash exercised.
Financing led by Novalis LifeSciences; includes participation from Northpond Ventures, BroadOak, and CEO affiliate M-185 Corp.
Paul Meister, partner at Novalis LifeSciences, appointed to board effective June 5, 2023, expanding board from 7 to 8 directors.
Proceeds to be used for general corporate purposes.

item 3.02 item 3.03 item 5.02 item 5.03 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Paul Meister

director

Telesis Bio Inc.

Effective: 2023-06-05
Filed: June 9, 2023, 7:59 PM ET

Paul Meister, a partner at Novalis LifeSciences LLC, was appointed as a director of the Company to fill the resulting vacancy.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Paul Meister was appointed as director at Telesis Bio Inc..

Action: appointed
Role: director

Exact text from the filing

Paul Meister, a partner at Novalis LifeSciences LLC, was appointed as a director of the Company to fill the resulting vacancy.

View on SEC.gov

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Telesis Bio Inc.: Filed Certificate of Designation establishing Redeemable Convertible Preferred stock.

Change: charter amendment

Exact text from the filing

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. In connection with the closing of the Private Placement, the Company filed with the Secretary of State of the State of Delaware the Certificate of Designation attached hereto as Exhibit 3.1 and incorporated herein by reference. The Certificate of Designation establishes and designates the Redeemable Convertible Preferred and the rights, preferences and privileges thereof.

View on SEC.gov

Browse all governance changes →

Source: SEC EDGAR

accession 0001193125-23-164515

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.